← Back to Search

Other

Aprepitant + Dexamethasone for Postoperative Nausea and Vomiting

N/A

Waitlist Available

Led By Dmitri Chamchad, MD

Research Sponsored by Main Line Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ASA physical status I-III

At least 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 hour, 2 hours, 24 hours after surgery

Awards & highlights

Study Summary

This trial found that adding aprepitant to dexamethasone improved the anti-nausea effect during surgery.

Who is the study for?

This trial is for adults over 18 who are in good to moderate health (ASA I-III) and have at least two risk factors for experiencing nausea and vomiting after surgery. It's not open to those who've taken anti-nausea meds in the last day, have allergies or contraindications to the study drugs, or are pregnant or breastfeeding.Check my eligibility

What is being tested?

The study is testing if a combo of Aprepitant and a lower dose of Dexamethasone works better than just Aprepitant alone for preventing throwing up and feeling nauseous after elective laparoscopic surgeries within the first 24 hours post-operation.See study design

What are the potential side effects?

Possible side effects may include reactions related to immune system suppression from Dexamethasone like increased infection risk, blood sugar changes, mood swings, insomnia, indigestion; Aprepitant could cause headaches, fatigue, hiccups.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My overall health is good to moderately impaired.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 hour, 2 hours, 24 hours after surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 hour, 2 hours, 24 hours after surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour, 2 hours, 24 hours after surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

the incidences of nausea, vomiting, need for rescue medication

Secondary outcome measures

incidences of unplanned hospital admission; duration of PACU stay

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Active ComparatorActive Control2 Interventions

Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting

Group II: Placebo ComparatorPlacebo Group2 Interventions

Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor

3,886 Previous Clinical Trials

5,054,503 Total Patients Enrolled

55 Trials studying Vomiting

28,055 Patients Enrolled for Vomiting

Drexel University College of MedicineOTHER

34 Previous Clinical Trials

3,922 Total Patients Enrolled

2 Trials studying Vomiting

115 Patients Enrolled for Vomiting

Main Line HealthLead Sponsor

20 Previous Clinical Trials

6,729 Total Patients Enrolled

Media Library

Aprepitant (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00835965 — N/A

Vomiting Research Study Groups: Placebo Comparator, Active Comparator

Vomiting Clinical Trial 2023: Aprepitant Highlights & Side Effects. Trial Name: NCT00835965 — N/A

Aprepitant (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00835965 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What medical conditions can Active Comparator effectively ameliorate?

"Through the use of Active Comparator, symptoms related to ophthalmia, sympathetic issues, branch retinal vein occlusion and macular edema can be effectively managed."

Answered by AI

Are there any participants being accepted currently for this research study?

"According to the information on clinicaltrials.gov, this medical trial is not presently seeking enrolment. Although it was initially posted on February 1st 2009 and subsequently updated two days later, there are currently 671 other trials recruiting patients now."

Answered by AI

To what extent are individuals participating in this experiment?

"Unfortunately, this medical trial is not currently accepting applications. The study was initially announced on the first of February 2009 and subsequently updated two days later. However, there are presently 114 trials actively recruiting participants experiencing nausea and 557 studies enrolling those with Active Comparator involvement."

Answered by AI

What further research has been conducted in regards to the Active Comparator methodology?

"Currently, there are 557 studies actively exploring the use of Active Comparator, with 144 clinical trials in Phase 3. Elk Grove Village, Illinois is one site outfitting research on this treatment; however, it can be accessed at 18663 locations across the world."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

2009. "Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00835965.

All > Cyclic Vomiting Syndrome